Presentation is loading. Please wait.

Presentation is loading. Please wait.

Presence of inpatient diagnostic codes for attributed cause of end-stage renal disease (ESRD) among 46 patients with systemic lupus erythematosus (SLE)

Published byBerenice Doyle Modified over 5 years ago

Similar presentations

Presentation on theme: "Presence of inpatient diagnostic codes for attributed cause of end-stage renal disease (ESRD) among 46 patients with systemic lupus erythematosus (SLE)"— Presentation transcript:

1 Presence of inpatient diagnostic codes for attributed cause of end-stage renal disease (ESRD) among 46 patients with systemic lupus erythematosus (SLE) in the Georgia Lupus Registry who progressed to ESRD (1979–2012) and had subsequent hospitalisations but ... Presence of inpatient diagnostic codes for attributed cause of end-stage renal disease (ESRD) among 46 patients with systemic lupus erythematosus (SLE) in the Georgia Lupus Registry who progressed to ESRD (1979–2012) and had subsequent hospitalisations but whose ESRD was not attributed to SLE. HTN, hypertension; DMII, diabetes mellitus type II; FSGS, focal segmental glomerulosclerosis; other GN, glomerulonephritis not attributed to SLE. Other includes tubular necrosis, IgA nephropathy, scleroderma, diabetes mellitus type I, multiple myeloma, other renal disorder and uncertain aetiology. Laura C Plantinga et al. Lupus Sci Med 2016;3:e000132 ©2016 by Lupus Foundation of America

Download ppt "Presence of inpatient diagnostic codes for attributed cause of end-stage renal disease (ESRD) among 46 patients with systemic lupus erythematosus (SLE)"

Similar presentations

© ANZDATA Registry CANCER CHAPTER CHAPTER 10. © ANZDATA Registry CharacteristicMyelomaNon-Myeloma n%n% Total (%)807153,37199 Country of residence Australia6908644,25683.

© ANZDATA Registry CANCER CHAPTER CHAPTER 10. © ANZDATA Registry CharacteristicMyelomaNon-Myeloma n%n% Total (%)807153,37199 Country of residence Australia ,25683.
NEW PATIENTS COMMENCING TREATMENTS IN 2010 CHAPTER 2.

NEW PATIENTS COMMENCING TREATMENTS IN 2010 CHAPTER 2.
ANZDATA Registry Annual Report 2013 NEW PATIENTS CHAPTER 2.

ANZDATA Registry Annual Report 2013 NEW PATIENTS CHAPTER 2.
Systemic diseases and the kidney Dr I.Sagiv M.D Nephrology & Hypertension services Hadassah-Hebrew university medical center Jerusalem.

Systemic diseases and the kidney Dr I.Sagiv M.D Nephrology & Hypertension services Hadassah-Hebrew university medical center Jerusalem.
Blair Grace Kylie Hurst Stephen McDonald CHAPTER 2 NEW PATIENTS COMMENCING TREATMENT IN 2011 2012 Annual Report—35th Edition ANZDATA Registry Annual Report.

Blair Grace Kylie Hurst Stephen McDonald CHAPTER 2 NEW PATIENTS COMMENCING TREATMENT IN Annual Report—35th Edition ANZDATA Registry Annual Report.
Chapter 1 Incidence of End Stage Kidney Disease 2014 ANZDATA Registry 37th Annual Report Data to 31-Dec-2013.

Chapter 1 Incidence of End Stage Kidney Disease 2014 ANZDATA Registry 37th Annual Report Data to 31-Dec-2013.
KDIGO guidelines glomerulonephritis Dr.. Overview Rationale for requirement of guidelines KDIGO: GN Guidelines  Scope Clinical Nephrology Conferences.

KDIGO guidelines glomerulonephritis Dr.. Overview Rationale for requirement of guidelines KDIGO: GN Guidelines  Scope Clinical Nephrology Conferences.
2016 Annual Data Report, Vol 2, ESRD, Ch 8

2016 Annual Data Report, Vol 2, ESRD, Ch 8
Characteristics of patients Without renal recovery

Characteristics of patients Without renal recovery
“Systemic Lupus Erythematosus” Renal features

“Systemic Lupus Erythematosus” Renal features
Overzicht van relevante classificatiesystemen in de nefropathologie

Overzicht van relevante classificatiesystemen in de nefropathologie
Odd ratio of developing kidney failure figure 1

Odd ratio of developing kidney failure figure 1
Volume 81, Issue 2, Pages (January 2012)

Volume 81, Issue 2, Pages (January 2012)
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use  Mei-Ling Blank, Lianne.

A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use  Mei-Ling Blank, Lianne.
Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.
Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.
Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.
Volume 94, Issue 5, Pages (November 2018)

Volume 94, Issue 5, Pages (November 2018)
Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.

Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.

Similar presentations

Ads by Google